Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...

Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.

Analysts at HC Wainwright issued their FY2029 EPS estimates for Galectin Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst E. Arce expects that the company will post ...

Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. Galectin Therapeutics ( NASDAQ:GALT – Get Free Report ) last posted its earnings results on Monday, March 31st.

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (GALT) (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial ...

(MENAFN- GlobeNewsWire - Nasdaq) NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins ...